Division of Pediatric Neonatology, Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
College of Medicine, Chang Gung University, Taoyuan, Taiwan.
BMC Infect Dis. 2018 Apr 24;18(1):194. doi: 10.1186/s12879-018-3100-2.
Invasive candidiasis differs greatly between children and neonates. We aimed to investigate the different therapeutic approaches and their effects on treatment outcomes of these two groups.
Episodes of neonatal invasive candidiasis were compared with non-neonatal pediatric episodes during a 12-year cohort study. Clinical isolates were documented by matrix-assisted laser desorption/ionization-time of flight mass spectrometry and DNA sequencing, and antifungal susceptibility testing was performed.
A total of 342 episodes of invasive candidiasis (113 neonatal and 229 non-neonatal pediatric episodes) in 281 pediatric patients (96 neonates and 185 children) were identified. Candida albicans was the most common pathogen causing invasive candidiasis in neonates and children (47.8% vs. 44.1%). The antifungal susceptibility profiles were not significantly different between neonates and children. More neonates received amphotericin B as therapy, whereas more children received fluconazole or caspofungin. Compared with children, neonates had a significantly longer duration of fungemia, higher rates of septic shock (34.5% vs. 21.8%; P = 0.013), sepsis-attributable mortality (28.3% vs. 17.5%; P = 0.024) and in-hospital mortality (42.7% vs. 25.4%; P = 0.004) than children. Independent risk factors for treatment failure of invasive candidiasis were septic shock (odds ration [OR] 16.01; 95% confidence interval [CI] 7.64-33.56; P < 0.001), delayed removal of intravenous catheter (OR 6.78; 95% CI 2.80-17.41; P < 0.001), renal failure (OR 5.38; 95% CI 1.99-14.57; P = 0.001), and breakthrough invasive candidiasis (OR 2.99; 95% CI 1.04-8.67; P = 0.043).
Neonatal invasive candidiasis has worse outcomes than non-neonatal pediatric candidiasis. Neonatologists and pediatricians must consider age-specific differences when developing treatment and prevention guidelines, or when interpreting studies of other age groups.
侵袭性念珠菌病在儿童和新生儿之间有很大差异。我们旨在研究这两个群体不同的治疗方法及其对治疗结果的影响。
在一项为期 12 年的队列研究中,比较了新生儿侵袭性念珠菌病与非新生儿儿科病例。通过基质辅助激光解吸/电离时间飞行质谱和 DNA 测序记录临床分离株,并进行抗真菌药敏试验。
在 281 名儿科患者(96 名新生儿和 185 名儿童)中发现了 342 例侵袭性念珠菌病(113 例新生儿和 229 例非新生儿儿科病例)。在新生儿和儿童中,白色念珠菌是引起侵袭性念珠菌病最常见的病原体(47.8% vs. 44.1%)。新生儿和儿童的抗真菌药敏谱无显著差异。更多的新生儿接受两性霉素 B 治疗,而更多的儿童接受氟康唑或卡泊芬净治疗。与儿童相比,新生儿的菌血症持续时间更长,败血症休克发生率更高(34.5% vs. 21.8%;P=0.013),败血症相关死亡率更高(28.3% vs. 17.5%;P=0.024),住院死亡率更高(42.7% vs. 25.4%;P=0.004)。侵袭性念珠菌病治疗失败的独立危险因素包括败血症休克(比值比[OR]16.01;95%置信区间[CI]7.64-33.56;P<0.001)、静脉导管延迟拔除(OR 6.78;95%CI 2.80-17.41;P<0.001)、肾功能衰竭(OR 5.38;95%CI 1.99-14.57;P=0.001)和突破性侵袭性念珠菌病(OR 2.99;95%CI 1.04-8.67;P=0.043)。
新生儿侵袭性念珠菌病的结局比非新生儿儿科念珠菌病差。新生儿科医生和儿科医生在制定治疗和预防指南或解释其他年龄组的研究时,必须考虑年龄特异性差异。